Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and PADMANEE SHARMA.
Connection Strength
1.622
-
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol. 2012 May 08; 9(6):302-3.
Score: 0.419
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
Score: 0.243
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
Score: 0.201
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.147
-
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
Score: 0.142
-
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
Score: 0.091
-
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009 Mar 15; 15(6):2130-9.
Score: 0.084
-
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
Score: 0.084
-
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92.
Score: 0.081
-
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007 Jun 26; 7:10.
Score: 0.075
-
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
Score: 0.055